RxDoctor Payments Data

Richard Santa Cruz, MD

Cardiovascular Disease · Appleton, WINPI 1861423758

Payments from drug & device makers

$8,682in general payments, 2019–2025

Across 193 payments — averaging $44.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Boston Scientific$2K
  • Edwards Lifesciences$953
  • Philips North America LLC$716
  • Abiomed$625
  • Medtronic$382
  • plus $1K from 23 others

What the payments were for

  • Travel & lodging$2,28426%
  • Food & beverage$6,39874%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,682 in reported general payments places this provider in the 75th percentile of 322 cardiovascular disease providers in Wisconsin.

See all cardiovascular disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$602,248
Medicare patients
1,145
Services billed
5,022

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban113$124,057
Repatha SureclickEvolocumab43$38,954
XareltoRivaroxaban30$27,296
EntrestoSacubitril/Valsartan22$24,881
BrilintaTicagrelor16$16,948
Praluent PenAlirocumab19$15,212
FarxigaDapagliflozin Propanediol11$10,555
ClopidogrelClopidogrel Bisulfate187$1,899
Metoprolol Succinate154$1,720
Rosuvastatin Calcium154$1,655
Losartan Potassium81$861
Atorvastatin Calcium108$853
Diltiazem 24hr Er (Cd)Diltiazem Hcl32$720
Bumetanide13$579
Isosorbide Mononitrate ErIsosorbide Mononitrate42$554

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$55$124,057113 claims
AstraZenecaBrilinta, Farxiga$18$27,50327 claims
Johnson & JohnsonXarelto$68$27,29630 claims
NovartisEntresto$158$24,88122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 322 cardiovascular disease providers in Wisconsin.

Other cardiovascular disease in Appleton

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →